Hexarelin

Background

Hexarelin (also called examorelin) is a synthetic growth hormone secretagogue from the growth hormone-releasing peptide (GHRP) family. It was developed during the peptide discovery programs that followed the identification of small synthetic compounds capable of stimulating pituitary growth hormone (GH) release without direct somatostatin inhibition. In the published literature, hexarelin is consistently described as a potent and metabolically stable GHRP with stronger GH-releasing activity than several earlier analogs, although it has not been approved as a medicinal product in the United States or European Union [2][11][15].

The peptide has been most extensively studied in endocrine physiology and preclinical cardiovascular research. Human data are limited and largely involve short-term pharmacodynamic studies in small cohorts rather than phase 3 development. Published work suggests that hexarelin’s biological profile extends beyond GH secretion to include direct cardiac and metabolic actions, but most of these findings remain investigational and preclinical [2][9][10][15].

Mechanism of action

Hexarelin acts primarily through the growth hormone secretagogue receptor type 1a (GHSR-1a), the ghrelin receptor, which is a G protein-coupled receptor expressed in the hypothalamus, pituitary, and multiple peripheral tissues [2][4][8]. Binding at GHSR-1a stimulates GH release and can also influence appetite, autonomic tone, and metabolic signaling through pathways shared with endogenous ghrelin [4][8].

A distinctive feature of hexarelin is that it also shows non-GHSR activity, particularly in the cardiovascular system. Review and experimental literature describe CD36 as an additional cardiac receptor involved in hexarelin-mediated cardioprotection, with downstream effects on myocardial survival signaling, oxidative stress, and inflammatory mediators [2][11]. In rat ischemia/reperfusion models, hexarelin’s protective actions were associated with modulation of interleukin-1 signaling, including down-regulation of IL-1β and up-regulation of IL-1Ra, and these effects were blocked by a GHSR antagonist in the cited study [3].

Hexarelin is also distinguished from endogenous ghrelin by its chemical stability and functional potency in experimental systems [2][11]. This has made it a useful probe for studying GH secretagogue pharmacology, even though it has not progressed to routine therapeutic use.

Evidence summary

The clinical evidence base for hexarelin is small and mostly consists of short-term physiologic studies. In one early human study in patients with homozygous β-thalassemia, hexarelin was reported to stimulate GH release; the article is frequently cited as part of the early human pharmacology literature, but the sample size and detailed endocrine endpoints are not available from the title record alone [1]. More broadly, reviews of growth hormone secretagogues emphasize that human experience with hexarelin remains limited and does not establish an approved clinical indication [15].

Most of the more influential evidence is preclinical:

• Cardiac ischemia/reperfusion injury in rats: In a rat model of in vivo myocardial ischemia/reperfusion, hexarelin treatment improved systolic function, reduced malondialdehyde production, and increased surviving cardiomyocytes. The study also reported regulation of IL-1 pathway mediators and concluded that the cardioprotective effect was stronger than equimolar ghrelin in that model [3].
• Experimental myocardial infarction in rats: A rat study published in Endocrinology found that hexarelin improved cardiac function after experimental myocardial infarction, supporting direct cardiac benefit beyond endocrine effects [10].
• Metabolic phenotype in insulin-resistant mice: In nonobese insulin-resistant male MKR mice, hexarelin improved lipid metabolic abnormalities, with the paper focusing on altered adipocyte/metabolic signaling and implicating CD36-related mechanisms [9][12].
• Skeletal muscle physiology: Earlier rat skeletal muscle work showed that growth hormone secretagogues, including hexarelin, modulated electrical and contractile properties through a ghrelin-specific receptor mechanism, suggesting broader tissue actions [13].
• Diabetic rat physiology: In streptozotocin-induced diabetic rats, daily hexarelin increased pulsatile GH secretion and altered metabolic hormones over two weeks, indicating endocrine activity in diabetes-related models [14].

Overall, the evidence supports potent GH secretagogue activity and a consistent pattern of cardiometabolic effects in animals, but there is no robust late-phase human efficacy dataset for any indication [1][15].

Clinical and research uses

Hexarelin has been used mainly as a research tool and experimental comparator in endocrine and cardiovascular studies [2][11][15]. Investigational uses described in the literature include:

• stimulation of GH secretion in human physiology studies [1][15]
• exploration of cardioprotection in ischemia/reperfusion and myocardial infarction models [3][10][11]
• mechanistic work on lipid metabolism and insulin resistance [9][12]
• evaluation of skeletal muscle and autonomic receptor signaling [13]
• endocrine-metabolic studies in diabetic animal models [14]

There is no established approved therapeutic indication for routine clinical use, and available studies do not support standard-of-care treatment for heart failure, myocardial infarction, diabetes, lipodystrophy, or GH deficiency [11][15]. Any use outside research settings would be considered investigational and potentially off-label or non-approved depending on jurisdiction.

Dosing context

Published dosing in the literature is variable and depends on model system and endpoint. In the accessible sources, reported preclinical regimens include 100 μg/kg/day subcutaneously for 7 days in rats after ischemia/reperfusion injury [3], 100 μg/kg/day intraperitoneally for 2 weeks in streptozotocin-diabetic rats [14], and twice daily intraperitoneal administration in MKR mice in the metabolic study [12].

Human dosing details are not well established in the accessible record from the cited studies, and no approved labeled dose exists because hexarelin is not an approved product in the US or EU [1][15]. For encyclopedia purposes, the literature supports only that dosing has been explored experimentally, not that a clinically validated dose is available.

Safety profile

Safety information is limited by the small size and short duration of human exposure. In the general growth hormone secretagogue literature, concerns include transient increases in GH and downstream insulin-like signaling, potential effects on glucose homeostasis, water retention, appetite stimulation, and neuroendocrine changes [4][15]. Because hexarelin has been studied predominantly in animals, the full human adverse-event profile is not well defined.

Reported or plausible adverse effects discussed in the class literature include:

• transient hyperglycemia or altered glucose control, especially in metabolically vulnerable patients [14][15]
• appetite stimulation and weight-related effects via ghrelin-pathway signaling [4]
• fluid retention and endocrine effects associated with GH release [15]
• theoretical cardiovascular interactions, including blood pressure and autonomic effects, because GHSR is expressed in cardiac and vascular tissue [2][11]

Contraindications are not formally established in an approved label. From the available literature, caution is generally warranted in patients with active malignancy, uncontrolled diabetes, or conditions in which GH/IGF-1 signaling could be undesirable, but these are inferred precautions rather than label-based contraindications [15]. No authoritative US or EU prescribing contraindication list is available for hexarelin because it is not authorized as a marketed medicine [15].

Regulatory status

Hexarelin is not approved in the United States by the FDA and is not approved in the European Union as a medicinal product. The available literature and review articles characterize it as an investigational peptide used in research rather than an authorized therapeutic agent [11][15]. Consequently, there is no formal FDA or EMA prescribing information, no approved commercial formulation for routine medical use, and no established labeled dosing or contraindication framework [15].